American Society of Retina Specialists (ASRS) 2016 Conference Review

In this review:

Aflibercept for neovascular AMD
Intermediate AMD, genetic risk and antioxidant supplementation
Ranibizumab and VA outcomes
Intravitreal aflibercept for previously treated macular oedema
VA outcomes with ranibizumab in retinal ischaemia
Intravitreal aflibercept in retinal vascular disease
Aflibercept for polypoidal choroidal vasculopathy
Aflibercept, bevacizumab, or ranibizumab for DMO
Ocriplasmin for vitreomacular traction
Intravitreal aflibercept injection for CNV

Please login below to download this issue (PDF)